HC Wainwright Predicts CareDx's Q1 Earnings (NASDAQ:CDNA)

CareDx, Inc (NASDAQ:CDNA - Free Report) - Stock analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of CareDx in a research report issued on Monday, March 3rd. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.21) per share for the quarter, down from their prior estimate of ($0.12). HC Wainwright currently has a "Neutral" rating and a $25.00 target price on the stock. The consensus estimate for CareDx's current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for CareDx's Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.50) EPS.

CareDx (NASDAQ:CDNA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $86.58 million during the quarter, compared to analyst estimates of $84.56 million.

CDNA has been the subject of several other reports. StockNews.com raised CareDx from a "hold" rating to a "buy" rating in a research note on Wednesday, February 26th. Stephens restated an "overweight" rating and set a $40.00 price target on shares of CareDx in a report on Thursday, February 27th. Finally, Wells Fargo & Company upgraded shares of CareDx from an "underweight" rating to an "equal weight" rating and dropped their price objective for the company from $28.00 to $24.00 in a research note on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, CareDx presently has an average rating of "Moderate Buy" and an average target price of $31.83.

Remove Ads

CareDx Stock Down 4.4 %

Shares of CDNA traded down $0.83 during mid-day trading on Thursday, reaching $18.09. The company's stock had a trading volume of 846,177 shares, compared to its average volume of 844,566. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -6.70 and a beta of 1.95. The business has a fifty day moving average of $22.56 and a 200 day moving average of $24.76. CareDx has a 1 year low of $7.42 and a 1 year high of $34.84.

Institutional Investors Weigh In On CareDx

A number of large investors have recently bought and sold shares of CDNA. Quarry LP bought a new stake in shares of CareDx during the 3rd quarter worth about $27,000. Sterling Capital Management LLC boosted its position in CareDx by 771.2% during the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock worth $27,000 after purchasing an additional 1,126 shares during the period. Harvest Fund Management Co. Ltd acquired a new position in CareDx during the third quarter valued at approximately $52,000. Tower Research Capital LLC TRC grew its holdings in CareDx by 553.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock valued at $84,000 after purchasing an additional 3,322 shares during the last quarter. Finally, State of Wyoming bought a new position in shares of CareDx in the fourth quarter valued at approximately $91,000.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.